Home / Going-concern warnings / Gain Therapeutics, Inc.
Filed 2026-08-11 路 Form 10-Q 路 Accession 0001104659-26-094048 micro
Price before filing: $1.77 (2026-08-10 close, split/dividend-adjusted)
Market cap at flag: $88.3M (2026-08-11) 路 Latest: $54.0M (2026-10-16)
| Window | GANX | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -3.4% | -2.0% | -1.4% | 2026-09-10 |
| 90 days | pending | pending | until 2026-11-09 | |
| 180 days | pending | pending | until 2027-02-07 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"Our projected cash outflows for the upcoming periods raise substantial doubt about our ability to continue as a going concern for at least 12 months from the issuance of the financial statements included elsewhere in this Quarterly Report."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2026-06-30)
Why this score: quarterly (unaudited) disclosure
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.